Targeting Two Types of Lymphoma
The FDA granted accelerated approval to a molecularly targeted therapeutic for certain patients with marginal zone lymphoma or follicular lymphoma.
Progress Against Cancer
The FDA granted accelerated approval to a molecularly targeted therapeutic for certain patients with marginal zone lymphoma or follicular lymphoma.
The FDA granted accelerated approval to a new oral targeted therapeutic to treat certain adult patients with the most common form of lung cancer.
The FDA approved the combination of an immune checkpoint inhibitor and a therapeutic that prevents tumors from growing blood vessels to treat certain patients with renal cell carcinoma. The U.S. Food and Drug Administration...
The FDA approved a molecularly targeted therapeutic for treating certain patients with some rare cancers affecting the gastrointestinal system. The U.S. Food and Drug Administration (FDA) has approved the molecularly targeted therapeutic fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the first oral gonadotropin-releasing hormone (GnRH)...
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a synthetic corticosteroid to treat certain patients with multiple myeloma. The U.S. Food and Drug Administration...
The U.S. FDA has approved a new targeted therapy for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies.
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with medullary thyroid cancer. The U.S. Food and Drug Administration has approved pralsetinib (Gavreto) to treat certain adult and pediatric patients age...
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer during their lifetime. While both the incidence and mortality rates have been steadily decreasing in...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More